Aurinia Pharmaceuticals’ LUPKYNIS Shows Promising Results in Lupus Nephritis Study

Aurinia Pharmaceuticals ( (AUPH) ) has issued an update.

Aurinia Pharmaceuticals announced new findings from a post-hoc analysis of the Phase 3 AURORA 1 study, demonstrating that lupus nephritis patients receiving triple immunosuppressive therapy with LUPKYNIS achieved significantly lower proteinuria levels compared to the control group. This suggests that LUPKYNIS-based therapy could lead to better long-term kidney health and reduced cardiovascular risk for patients, reinforcing its critical role in improving health outcomes for lupus nephritis patients.

The most recent analyst rating on (AUPH) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.

Spark’s Take on AUPH Stock

According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.

Aurinia Pharmaceuticals scores well due to its strong financial performance and positive earnings call highlights, underscoring robust revenue growth and profitability. Technical analysis suggests moderate momentum, but the high valuation and ongoing market challenges such as patent litigation and competitive pressures present notable risks. While the company’s operational efficiency and financial health are commendable, investors should remain cautious of external risks.

To see Spark’s full report on AUPH stock, click here.

More about Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies to treat autoimmune diseases. The company’s primary product, LUPKYNIS, is a second-generation calcineurin inhibitor used as an immunosuppressant to treat lupus nephritis, a severe kidney inflammation caused by systemic lupus erythematosus.

Average Trading Volume: 1,449,257

Technical Sentiment Signal: Buy

Current Market Cap: $1.12B

See more insights into AUPH stock on TipRanks’ Stock Analysis page.